Rx0000063 |
Ferring Pharmaceuticals |
06/30/2022 |
55566280001 |
CERVIDIL 10MG VAGINAL INSERT (Dinoprostone 10MG) |
04/01/2022 |
22.85 |
479.84 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The acquisition fields do not apply because Ferring did not acquire the product within the past five years. |
Rx0000063 |
Ferring Pharmaceuticals |
06/30/2022 |
55566750102 |
Menopur (Menotropins for injection)/75 nits/vial - 5 single dose vials per package |
06/01/2022 |
32.70 |
1122.15 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The acquisition fields do not apply because Ferring did not acquire the product within the past five years. NDC 55566750101 is the NDC for the 0.9% Sodium Chloride Injection, USP, 2 mL product included in the Menopur kit. The Sodium Chloride is used for mixing the medicine. NDC 55566750101 does not have a WAC price |
Rx0000193 |
Forte Bio-Pharma, LLC |
03/31/2022 |
72245019310 |
NALOCET 2.5MG/300MG 100CT TABLETS |
01/01/2022 |
132.19 |
2776.04 |
None |
Non-innovator Multiple Source Drug |
4200 |
None |
Forte Bio considers many factors in the pricing of our products including but not limited to constant competition in the marketplace requires frequent reassements of pricing to ensure consistency with current market, market share has a determining factor on our pricing as we determine our pricing structure to ensure our place in the market, patient population contributes to each pricing decision as this helps determine the profitability of the product and the cost to market our products is continuously rising as we need more resources to properly market the products. |
None |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000129 |
Fresenius Kabi USA LLC |
12/31/2022 |
63323061603 |
Amiodarone HCl Intravenous Solution 150 MG/3ML Package Size 25 |
12/09/2022 |
5.25 |
43.75 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000129 |
Fresenius Kabi USA LLC |
03/31/2022 |
63323051610 |
Dexamethasone Sodium Phosphate Inj 100mg 10mL MDV 10 10ML Vials |
01/07/2022 |
12.30 |
141.50 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000129 |
Fresenius Kabi USA LLC |
03/31/2022 |
63323050601 |
Dexamethasone Sodium Phosphate Inj 10mg 1mL PF SDV 1 25ML Vial |
01/07/2022 |
14.75 |
171.25 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000129 |
Fresenius Kabi USA LLC |
12/31/2022 |
63323016530 |
Dexamethasone Sodium Phosphate Injection Solution 120 MG/30ML Package Size 1 |
12/09/2022 |
3.53 |
40.71 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000129 |
Fresenius Kabi USA LLC |
12/31/2022 |
76045010610 |
Dexamethasone Sodium Phosphate Injection Solution 4 MG/ML Package Size 24 |
11/23/2022 |
31.86 |
69.36 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000129 |
Fresenius Kabi USA LLC |
03/31/2022 |
63323017302 |
Gentamicin Inj 20mg 2mL PF MDV 2 25ML Vials |
01/07/2022 |
10.25 |
117.50 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000129 |
Fresenius Kabi USA LLC |
09/30/2022 |
63323017394 |
Gentamicin Sulfate Injection Solution 10 MG/ML |
07/01/2022 |
3.75 |
49.50 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000129 |
Fresenius Kabi USA LLC |
12/31/2022 |
63323085110 |
HYDROmorphone HCl PF Injection Solution 10 MG/ML Package Size 10 |
12/09/2022 |
7.80 |
47.00 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000129 |
Fresenius Kabi USA LLC |
12/31/2022 |
76045000120 |
Midazolam HCl (PF) Injection Solution 2 MG/2ML Package Size 24 |
11/23/2022 |
18.00 |
66.00 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000129 |
Fresenius Kabi USA LLC |
03/31/2022 |
63323001230 |
Oxytocin Inj 300USP 30mL MDV 1 Vial |
01/07/2022 |
37.50 |
432.50 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000129 |
Fresenius Kabi USA LLC |
12/31/2022 |
63323018620 |
Sodium Chloride (PF) Injection Solution 0.9 % Package Size 25 |
12/09/2022 |
6.00 |
45.75 |
None |
Non-innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000129 |
Fresenius Kabi USA LLC |
03/31/2022 |
49230064551 |
Velphoro 90 Count Per Bottle of 500 MG Oral Tablets Chewable |
01/07/2022 |
57.74 |
1501.25 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000129 |
Fresenius Kabi USA LLC |
03/31/2022 |
63323048257 |
Xylocaine (Lidocaine HCl) Inj w EPI 500mg 50mL MDV 25pk Single Vial |
01/07/2022 |
20.50 |
236.25 |
None |
Single Source Drug |
None |
1 |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Rx0000100 |
Fresenius Medical Care |
09/30/2022 |
49230064551 |
VELPHORO 500MG CHEWABLE TABLETS 90 TABLET BOTTLE |
09/01/2022 |
30.03 |
1531.28 |
05/26/2035 |
Single Source Drug |
None |
1 |
The increase in Wholesale Acquisition Cost (WAC) for the products is due to increases in the costs of manufacturing and distribution, specifically including increases in the cost of the active pharmaceutical ingredients (API) of the products, increases in shipping for the products, and increases in costs to market the products. |
None |
This WAC increase is not necessitated by a change or improvement in the prescription drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Please note that this report and its contents are exempted from disclosure under the California Public Records Act, Cal. Gov. Code ? 6250 et seq. (?PRA?) as the material contains and constitutes FUSA?s proprietary commercial information and otherwise would not be in the public interest to disclose. Please contact Domenic Gaeta at domenic.gaeta@fmc-na.com regarding any PRA requests so that we may take appropriate steps to protect such information.
Fresenius Medical Care is the authorized distributor for Velphoro.
Fresenius Medical Care did not acquire Velphoro in the prior five year period. |